Integrum Launches Service Initiative to Strengthen U.S. Market Growth
Integrum AB (publ), ticker INTEG, a leader in medical technology and developer of the bone-anchored OPRA® Implant System, announces the launch of a new service initiative to enhance warranty and service support for its Axor™ II devices. This initiative is a critical step in advancing Integrum’s expansion in the U.S. market and driving sustainable growth.
The new program focuses on significantly reducing service turnaround times and delivering a streamlined, efficient customer experience for Axor™ II devices in the U.S. With this initiative, Integrum aims to provide unmatched support to clinicians and amputees, ensuring continuity of care and optimal device performance.
“This initiative is a key milestone in strengthening our U.S. presence, improving customer satisfaction, and helping providers maximize the value of our solutions,” said Scott Flora, CEO of Integrum.
As Integrum accelerates its U.S. market expansion, the company remains dedicated to empowering amputees and supporting clinicians who deliver life-changing care.
For more information,
Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: Jorgen.svanstrom@integrum.se
Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser.
About Integrum
Integrum is a publicly traded company (Nasdaq First North Growth Market: INTEG B) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA® Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA® Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. OPRA® Implant System is a registered trademark of Integrum AB in the European Union.
To learn more, please visit https://integrum.se/.